---
layout: default
title: Ammonium Chloride
parent: 僅模型預測 (L5)
nav_order: 49
evidence_level: L5
indication_count: 2
---

# Ammonium Chloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **2** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ammonium Chloride: From Traditional Expectorant to Acute Laryngopharyngitis

## One-Sentence Summary

Ammonium chloride is a traditional expectorant with a long history of use for thinning respiratory mucus secretions, though it currently holds no approved indications on the Taiwan market.
The TxGNN model predicts it may be effective for **acute laryngopharyngitis**, with mechanistic plausibility rooted in its secretagogue action on airway glands.
However, this prediction is supported by **0 clinical trials** and **0 publications**, making this a model-only hypothesis requiring significant validation before any clinical consideration.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Traditional expectorant (not currently approved in Taiwan) |
| Predicted New Indication | Acute Laryngopharyngitis |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Taiwan Market Status | ✗ Not Marketed (未上市) |
| Number of Licenses | 0 |
| Recommended Decision | Hold |

---

## Why Is This Prediction Reasonable?

Ammonium chloride has historically been classified as an expectorant. Its proposed mechanism operates indirectly: oral administration irritates the gastric mucosa, triggering a vagal reflex that stimulates serous secretion from bronchial and upper airway glands. This action theoretically thins and loosens viscous mucus in the throat and laryngopharynx, which is a hallmark of acute laryngopharyngitis.

The connection between ammonium chloride and acute laryngopharyngitis is therefore mechanistically plausible at a conceptual level — both involve the upper airway, and mucus management is a central symptom management target in laryngopharyngeal inflammation. This mechanistic bridge is the most likely reason TxGNN assigned a high score (0.9994), as the knowledge graph likely contains strong associations between "respiratory secretagogue drugs" and "upper respiratory tract conditions" as a broad node cluster.

That said, it is important to note that detailed pharmacological mechanism of action data is unavailable for this drug in the current evidence pack. The mechanistic link described above is an indirect inference based on the drug's traditional use class. Furthermore, the TxGNN rank of 1,662 (despite the high score) suggests this prediction may reflect broad categorical similarity in the graph rather than a disease-specific signal. The complete absence of any registered clinical trial or published literature means this hypothesis has not been tested in any rigorous or even exploratory clinical setting.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Taiwan Market Information

Ammonium chloride currently holds **no approved licenses** on the Taiwan market and is classified as **not marketed (未上市)**. There are no DIN-equivalent license entries to display.

---

## Safety Considerations

Please refer to the package insert for safety information.

> No key warnings, contraindications, or drug interaction data are currently available in this evidence pack. Retrieval from TFDA product monographs and DrugBank is recommended before any further evaluation proceeds.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This is a model-only prediction (Evidence Level L5) with zero supporting clinical trials or published literature. While the mechanistic hypothesis connecting ammonium chloride's expectorant action to acute laryngopharyngitis is conceptually coherent, the complete absence of empirical evidence — combined with no Taiwan market presence and no safety data — makes advancement premature at this stage.

**To proceed, the following is needed:**

- **Safety data retrieval (Blocking):** Obtain TFDA product monograph (仿單) or equivalent international package insert to identify key warnings and contraindications before any clinical planning
- **MOA confirmation (High priority):** Query DrugBank API for pharmacodynamic mechanism of action to validate or refute the vagal reflex secretagogue hypothesis
- **Scoping literature search:** Conduct a broad PubMed search using ammonium chloride with upper respiratory tract, expectorant, and laryngitis terms to determine if any historical or regional literature exists outside the current search scope
- **Differentiation from second prediction:** Evaluate whether nasal cavity disease (rank 2, score 99.93%) or acute laryngopharyngitis is a more clinically actionable starting point, given that both currently share identical L5 evidence status
- **Regulatory pathway assessment:** Determine whether ammonium chloride could realistically re-enter the Taiwan market as a component in a combination expectorant product, given its historical role in cough-cold formulations globally
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

